Literature DB >> 32388776

Long Non-coding RNAs in Pulmonary Neuroendocrine Neoplasms.

Damodaran Narayanan1, Rakesh Mandal1, Heather Hardin1, Vishal Chanana1, Michael Schwalbe1, Jason Rosenbaum1, Darya Buehler1, Ricardo V Lloyd2.   

Abstract

Pulmonary neuroendocrine neoplasms (NENs) are classified into low-grade neuroendocrine tumors and high-grade neuroendocrine carcinomas (NECs). There are significant differences in therapeutic strategies of the different NEN subtypes, and therefore, precise classification of pulmonary NENs is critical. However, challenges in pulmonary NEN classification include overlap of diagnostic histological features among the subtypes and reduced or negative expression of neuroendocrine markers in poorly differentiated pulmonary NECs. Recently, transcription factor insulinoma-associated protein 1 (INSM1) was identified as a sensitive marker of neuroendocrine and neuroepithelial differentiation. In this study, INSM1 expression was detected by immunohistochemistry in greater than 94% of pulmonary NENs, indicating that it is a highly sensitive marker of pulmonary NENs and is useful to detect poorly differentiated pulmonary NECs. Although there are well-established morphological and immunohistologic criteria to diagnose pulmonary NENs, there is no universal consensus regarding prognostic markers of pulmonary NENs. Studies have shown that non-small cell lung cancers express long non-coding RNAs (lncRNAs), which regulate gene expression, epithelial-to-mesenchymal transition, and carcinogenesis. We characterized expression and function of lncRNAs, including HOX transcript antisense RNA (HOTAIR), maternally expressed 3 (MEG3), and prostate cancer antigen 3 (PCA3) in pulmonary NENs, including typical carcinoid tumors, atypical carcinoid tumors, small cell lung carcinoma (SCLC/NEC), and large cell neuroendocrine carcinoma (LCNEC/NEC). In situ hybridization and real-time polymerase chain reaction studies showed higher expression (p < 0.01) of all lncRNAs in SCLC/NEC. Small interfering RNA studies indicated a role for MEG3 and PCA3 in tumor proliferation. Therefore, these lncRNAs may serve as prognostic indicators of pulmonary NEN aggressiveness and as possible therapeutic targets.

Entities:  

Keywords:  INSM1; Long non-coding RNA; Pulmonary neuroendocrine neoplasms

Mesh:

Substances:

Year:  2020        PMID: 32388776     DOI: 10.1007/s12022-020-09626-1

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  5 in total

Review 1.  Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites.

Authors:  Silvia Uccella; Stefano La Rosa; Jasna Metovic; Deborah Marchiori; Jean-Yves Scoazec; Marco Volante; Ozgur Mete; Mauro Papotti
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

Review 2.  Molecular Pathology of Well-Differentiated Pulmonary and Thymic Neuroendocrine Tumors: What Do Pathologists Need to Know?

Authors:  Marco Volante; Ozgur Mete; Giuseppe Pelosi; Anja C Roden; Ernst Jan M Speel; Silvia Uccella
Journal:  Endocr Pathol       Date:  2021-02-27       Impact factor: 3.943

3.  Analysis on the Effects of CT- and Ultrasound-Guided Percutaneous Transthoracic Needle Biopsy Combined with Serum CA125 and CEA on the Diagnosis of Lung Cancer.

Authors:  Zhaoyin Wang; Jinbiao Huang; Minke Wang; Weixu Bi; Tianbing Fan
Journal:  J Healthc Eng       Date:  2022-01-07       Impact factor: 2.682

4.  MEG3 LncRNA from Exosomes Released from Cancer-Associated Fibroblasts Enhances Cisplatin Chemoresistance in SCLC via a MiR-15a-5p/CCNE1 Axis.

Authors:  Yulu Sun; Guijun Hao; Mengqi Zhuang; Huijuan Lv; Chunhong Liu; Keli Su
Journal:  Yonsei Med J       Date:  2022-03       Impact factor: 2.759

Review 5.  INSM1, a Novel Biomarker for Detection of Neuroendocrine Neoplasms: Cytopathologists' View.

Authors:  Zahra Maleki; Akash Nadella; Mohnish Nadella; Gopi Patel; Shivni Patel; Ivana Kholová
Journal:  Diagnostics (Basel)       Date:  2021-11-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.